Federal Circuit: PTAB Erred In Presuming Nexus Where Commercial Product Was Not Coextensive With Patented Invention

Dec 27, 2019

Reading Time : 2 min

SRAM, LLC (“Patent Owner”) is the owner of Patent No. 9,182,027 (the ’027 Patent), which claims an improved bicycle chainring structure that maintains the bicycle chain in place better than existing chainrings. The claims at issue recite specific features, including alternating narrow and wide tooth tips and teeth offset from the center of the chainring. The claims do not, however, require additional chainring improvements identified in the specification, including an “80% gap-filling” feature. During IPR of a related patent, Patent Owner referred to this feature as “critical.”

Petitioner FOX Factory, Inc. filed two (simultaneous) IPR petitions requesting review of claims 1-26 of the ’027 Patent. Petitioner asserted a number of grounds alleging that the claims would have been obvious based on several prior art references. The PTAB instituted review on both petitions. In response, Patent Owner introduced evidence of a number of secondary considerations, relying on certain chainring products that allegedly embodied the invention. The PTAB found that a combination of prior art references disclosed every limitation of the independent claims at issue, and that a skilled artisan would have been motivated to combine those references. Nonetheless, in light of Patent Owner’s objective evidence, the PTAB determined that Petitioner failed to show that the challenged claims would have been obvious.

On appeal, the Federal Circuit found that the PTAB had applied the wrong standard to determine whether there was a presumption of nexus between the challenged claims and the objective evidence. Objective evidence is only given substantial weight if there is a nexus between that evidence and the challenged claims. When the objective evidence includes a product allegedly embodying a claim, a court presumes there is a nexus between the product and the claim if the product is “coextensive” with the claim. In this case, the PTAB interpreted the coextensiveness requirement to mean only that the claims must broadly cover the product. The Federal Circuit disagreed with that interpretation. The court explained that the mere presence of some unclaimed features in the product will not necessarily preclude a presumption of nexus—indeed, perfect correspondence between a product and a claim is rare. But a patent owner must show that the product is essentially the claimed invention. Here, the product in question included a number of unclaimed features that materially impacted the functionality of the product, and the Federal Circuit could not conclude that the product was the invention claimed in the ’027 Patent that would trigger a presumption of nexus. Accordingly, the burden to show sufficient nexus should have remained with Patent Owner. The Federal Circuit remanded for the PTAB to consider secondary consideration under the appropriate allocation of the burden.

Practice Tip: Patent owners relying on a product to show evidence of secondary considerations should assess whether the product embodies critical unclaimed features. If so, a patent owner would be well advised to include ample evidence of nexus when arguing nonobviousness, instead of simply relying on a presumption of nexus.

Fox Factory, Inc. v. SRAM, LLC, No. 2018-2024/2018-2025 (Fed. Cir. Dec. 18, 2019)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.